Psych MEQs / SAQs · Specialty psychiatry — sexual medicine interface
Erectile disorder and premature ejaculation — assessment and management (MEQ)
FRANZCP-style MEQ covering organic ED, concurrent PE, nitrate/GTN safety, SSRI effects, and stepped management. FRANZCP-primary, globally tagged.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Formulation. Acquired, likely generalised erectile disorder with strong organic contribution: progressive course, absent morning erections, diabetes, and vascular (angina) risk. Performance anxiety and depressive illness may amplify failure (mixed model). Short latency when erection is partial is consistent with acquired PE secondary to ED and anticipatory rushing — not necessarily lifelong primary PE alone. Sertraline may further alter desire/orgasm timing; depression itself also impairs sexual function.[2][3][5][6]
(ii) Assessment priorities. Structured sexual history (phase map, lifelong/acquired, situational factors); IIEF for ED severity; estimated IELT and PE distress; full medication/substance list; angina pattern and all nitrate products including GTN spray; diabetes control; smoking/alcohol; suicide risk linked to shame; partner factors. Baseline labs as indicated (HbA1c already high — optimise; lipids; morning testosterone if hypogonadism clues). Coordinate GP/cardiology for CV risk.[2][5]
(iii) PDE5 inhibitor suitability. Sildenafil has robust efficacy evidence for ED but is contraindicated with concurrent nitrates (including GTN spray) because of severe hypotension risk. Do not prescribe PDE5i while nitrate therapy remains. Arrange cardiology/GP review of anti-anginal regimen and overall CV fitness for sexual activity before any future PDE5i trial; educate him not to self-source online PDE5i while holding GTN.[1][2]
(iv) Ejaculatory and antidepressant issues. ISSM pearl: treat ED first when PE coexists — improving erection quality may reduce rushed ejaculation. Behavioural methods (stop-start/squeeze, sensate focus, couple work) once medically safer. Do not start PE-directed SSRIs uncritically while already on sertraline with incomplete depression response — consider whole-regimen review (dose, switch options, sexual SE counselling) rather than stacking serotonergic agents blindly. Dapoxetine only where licensed and after ED/nitrate issues resolved.[3][4][6]
(v) Disposition and safety-net. Shared care with GP for diabetes/CVD optimisation; cardiology before PDE5i; psychosexual pathway; psychiatric follow-up for depression and sexual function; crisis contacts if suicidal ideation emerges; urgent care advice for chest pain during sexual activity and for priapism if future erectile drugs are used. Written plan: no PDE5i with GTN.[1][2][6]
Common errors
- Prescribing sildenafil despite GTN/nitrates.
- Labelling pure psychogenic ED despite diabetes, progressive course, and absent morning erections.
- Treating PE pharmacologically before addressing ED and nitrate safety.
- Ignoring sertraline's contribution to sexual dysfunction.
- Missing suicide risk and partner dynamics. [1][3][4]
References
- [1]Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group N Engl J Med, 1998.PMID 9580646
- [2]Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline J Urol, 2018.PMID 29746858
- [3]Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE) J Sex Med, 2014.PMID 24848686
- [4]Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients J Clin Psychiatry, 2001.PMID 11229449
- [5]McCabe MP, Sharlip ID, Lewis R, et al. Risk Factors for Sexual Dysfunction Among Women and Men: A Consensus Statement From the Fourth International Consultation on Sexual Medicine 2015 J Sex Med, 2016.PMID 26953830
- [6]Clayton AH, El Haddad S, Iluonakhamhe JP, et al. Sexual dysfunction associated with major depressive disorder and antidepressant treatment Expert Opin Drug Saf, 2014.PMID 25148932